130 related articles for article (PubMed ID: 18534873)
1. Genetic profile identification in clinically localized prostate carcinoma.
Gallucci M; Merola R; Leonardo C; De Carli P; Farsetti A; Sentinelli S; Sperduti I; Mottolese M; Carlini P; Vico E; Simone G; Cianciulli A
Urol Oncol; 2009; 27(5):502-8. PubMed ID: 18534873
[TBL] [Abstract][Full Text] [Related]
2. Cytogenetic profiles as additional markers to pathological features in clinically localized prostate carcinoma.
Gallucci M; Merola R; Farsetti A; Orlandi G; Sentinelli S; De Carli P; Leonardo C; Carlini P; Guadagni F; Sperduti I; Cianciulli AM
Cancer Lett; 2006 Jun; 237(1):76-82. PubMed ID: 16002207
[TBL] [Abstract][Full Text] [Related]
3. Fluorescence in situ hybridization analysis of c-myc amplification in stage TNM prostate cancer in Japanese patients.
Sato H; Minei S; Hachiya T; Yoshida T; Takimoto Y
Int J Urol; 2006 Jun; 13(6):761-6. PubMed ID: 16834657
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ-confined prostate cancer.
Tsuchiya N; Slezak JM; Lieber MM; Bergstralh EJ; Jenkins RB
Genes Chromosomes Cancer; 2002 Aug; 34(4):363-71. PubMed ID: 12112525
[TBL] [Abstract][Full Text] [Related]
5. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression.
Qian J; Hirasawa K; Bostwick DG; Bergstralh EJ; Slezak JM; Anderl KL; Borell TJ; Lieber MM; Jenkins RB
Mod Pathol; 2002 Jan; 15(1):35-44. PubMed ID: 11796839
[TBL] [Abstract][Full Text] [Related]
6. A molecularly genetic determination of prognostic factors of the prostate cancer and their relationships to expression of protein p27kip1.
Dvorácková J; Uvírová M
Neoplasma; 2007; 54(2):149-54. PubMed ID: 17319789
[TBL] [Abstract][Full Text] [Related]
7. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization.
Jenkins RB; Qian J; Lieber MM; Bostwick DG
Cancer Res; 1997 Feb; 57(3):524-31. PubMed ID: 9012485
[TBL] [Abstract][Full Text] [Related]
8. Aneusomies of chromosomes 8 and Y detected by fluorescence in situ hybridization are prognostic markers for pathological stage C (pt3N0M0) prostate carcinoma.
Takahashi S; Alcaraz A; Brown JA; Borell TJ; Herath JF; Bergstralh EJ; Lieber MM; Jenkins RB
Clin Cancer Res; 1996 Jan; 2(1):137-45. PubMed ID: 9816100
[TBL] [Abstract][Full Text] [Related]
9. Detection of chromosomal anomalies and c-myc gene amplification in the cribriform pattern of prostatic intraepithelial neoplasia and carcinoma by fluorescence in situ hybridization.
Qian J; Jenkins RB; Bostwick DG
Mod Pathol; 1997 Nov; 10(11):1113-9. PubMed ID: 9388062
[TBL] [Abstract][Full Text] [Related]
10. Aneusomy of chromosomes 7, 8, and 17 and amplification of HER-2/neu and epidermal growth factor receptor in Gleason score 7 prostate carcinoma: a differential fluorescent in situ hybridization study of Gleason pattern 3 and 4 using tissue microarray.
Skacel M; Ormsby AH; Pettay JD; Tsiftsakis EK; Liou LS; Klein EA; Levin HS; Zippe CD; Tubbs RR
Hum Pathol; 2001 Dec; 32(12):1392-7. PubMed ID: 11774175
[TBL] [Abstract][Full Text] [Related]
11. Deletions on chromosome 8p22 may predict disease progression as well as pathological staging in prostate cancer.
Matsuyama H; Pan Y; Oba K; Yoshihiro S; Matsuda K; Hägarth L; Kudren D; Naito K; Bergerheim US; Ekman P
Clin Cancer Res; 2001 Oct; 7(10):3139-43. PubMed ID: 11595707
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of allelic imbalance of chromosome arms 7q, 8p, 16q, and 18q in stage T3N0M0 prostate cancer.
Jenkins R; Takahashi S; DeLacey K; Bergstralh E; Lieber M
Genes Chromosomes Cancer; 1998 Feb; 21(2):131-43. PubMed ID: 9491325
[TBL] [Abstract][Full Text] [Related]
13. 8q24 amplification is associated with Myc expression and prostate cancer progression and is an independent predictor of recurrence after radical prostatectomy.
Fromont G; Godet J; Peyret A; Irani J; Celhay O; Rozet F; Cathelineau X; Cussenot O
Hum Pathol; 2013 Aug; 44(8):1617-23. PubMed ID: 23574779
[TBL] [Abstract][Full Text] [Related]
14. Relative copy number gain of MYC in diagnostic needle biopsies is an independent prognostic factor for prostate cancer patients.
Ribeiro FR; Henrique R; Martins AT; Jerónimo C; Teixeira MR
Eur Urol; 2007 Jul; 52(1):116-25. PubMed ID: 17070983
[TBL] [Abstract][Full Text] [Related]
15. [Relationship between chromosome 8 alterations and Gleason score in prostatic adenocarcinoma].
Zeng X; Wu SF; Xu Q; Xiao Y; Liu TH
Zhonghua Bing Li Xue Za Zhi; 2006 Sep; 35(9):523-8. PubMed ID: 17134545
[TBL] [Abstract][Full Text] [Related]
16. Molecular biological analysis of the heterogeneous prostate cancer group Gleason score 7.
Mian C; Lodde M; Comploj E; Palermo S; Lusuardi L; Marziani F; Chiocchetti A; Spada A; Mian M; Pycha A
Prostate; 2006 Jun; 66(9):966-70. PubMed ID: 16541423
[TBL] [Abstract][Full Text] [Related]
17. The role of chromosome 8p22 deletion for predicting disease progression and pathological staging in prostate cancer.
Matsuyama H; Pan Y; Oba K; Yoshihiro S; Matsuda K; Hägarth L; Kudren D; Naito K; Bergerheim US; Ekman P
Aktuelle Urol; 2003 Jul; 34(4):247-9. PubMed ID: 14566675
[TBL] [Abstract][Full Text] [Related]
18. Fluorescence in situ hybridization analysis of 8p allelic loss and chromosome 8 instability in human prostate cancer.
Macoska JA; Trybus TM; Sakr WA; Wolf MC; Benson PD; Powell IJ; Pontes JE
Cancer Res; 1994 Jul; 54(14):3824-30. PubMed ID: 8033102
[TBL] [Abstract][Full Text] [Related]
19. Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer.
El Gammal AT; Brüchmann M; Zustin J; Isbarn H; Hellwinkel OJ; Köllermann J; Sauter G; Simon R; Wilczak W; Schwarz J; Bokemeyer C; Brümmendorf TH; Izbicki JR; Yekebas E; Fisch M; Huland H; Graefen M; Schlomm T
Clin Cancer Res; 2010 Jan; 16(1):56-64. PubMed ID: 20028754
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of chromosome 8p, 10q, and 16q deletions in prostate cancer.
Matsuyama H; Pan Y; Yoshihiro S; Kudren D; Naito K; Bergerheim US; Ekman P
Prostate; 2003 Feb; 54(2):103-11. PubMed ID: 12497583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
